Show simple item record

dc.contributor.authorMAPS group
dc.date.accessioned2020-08-17T12:30:02Z
dc.date.available2020-08-17T12:30:02Z
dc.date.issued2020-09
dc.identifier.citationMAPS group 2020 , ' Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS) : a multicentre, three-arm, randomised controlled pilot and feasibility study ' , The lancet. Psychiatry , vol. 7 , no. 9 , pp. 788-800 . https://doi.org/10.1016/S2215-0366(20)30248-0en
dc.identifier.issn2215-0366
dc.identifier.otherPURE: 174044548
dc.identifier.otherPURE UUID: 595ce317-9066-4427-a7aa-23b765eebba2
dc.identifier.otherPubMed: 32649925
dc.identifier.otherScopus: 85088381551
dc.identifier.otherWOS: 000564105900031
dc.identifier.urihttps://hdl.handle.net/2164/14938
dc.descriptionFunding Information: MAPS was funded by the UK National Institute for Health Research under its Health Technology Assessment Programme following a commissioned call (project number 15/31/04). The call specified the interventions, population, setting, study design, and main outcomes. The funder of the study had no role in data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Funding Information: APM reports personal fees from training workshops in cognitive behavioural therapy (CBT) for psychosis and royalties from books on the topic, outside of the submitted work. MP reports personal fees and fees paid to the Psychosis Research Unit of Greater Manchester Mental Health NHS Foundation Trust for CBT training outside of the submitted work. LJ reports personal fees from New Harbinger Publications, outside of the submitted work. DFr reports grants from the National Institute for Health Research (NIHR) and the UK Medical Research Council outside of the submitted work. MRB reports royalties from Oxford University Press and personal fees from the UK Medical Defence Union, outside of the submitted work. NH is the chair of the board of trustees of the Manchester Global Foundation, a Charitable Incorporated Organisation registered in England and Wales; is a past trustee of Lancashire Mind, the Pakistan Institute of Living and Learning, and the Abaseen Foundation; established an independent general hospital (Remedial Centre) in Karachi, Pakistan, which is now owned and operated by his sibling with a pharmacy attached; and received honoraria and travel grants from Eli Lilly, Bristol Myers Squibb, Lundbeck, AstraZeneca, and Janssen Pharmaceuticals outside of the submitted work. GM reports grants from the NIHR Health Technology Assessment (HTA) Programme during the conduct of the study. JN reports membership in the NIHR boards: Efficacy and Mechanisms Evaluation Board (2019–present), Commissioning Priority Review Decision-Making Committee (2015), HTA Commissioning Board (2010–16), HTA Commissioning Sub-Board (Expression of Interest; 2014), HTA Funding Boards Policy Group (2016–19), HTA General Board (2016–19), HTA Post-Board Funding Teleconference (2016–19), NIHR Clinical Trials Unit Standing Advisory Committee (2018–present), NIHR HTA and Efficacy and Mechanism Evaluation Editorial Board (2014–19), and Pre-exposure Prophylaxis Impact Review Panel (2017); outside of the submitted work. DS reports personal fees from the National Clinical Audit of Psychosis of the Royal College of Psychiatrists, royalties from Wiley Blackwell publication for the book Promoting Recovery in Early Psychosis , membership in the current National Institute for Health and Care Excellence (NICE) guideline development group for rehabilitation in adults with complex psychosis and related severe mental health conditions, and current board membership at the UK National Collaborating Centre for Mental Health, outside of the submitted work. CH was chair of the NICE guideline development group for schizophrenia in children and young people (2011–13) and was chair of the NICE psychosis and schizophrenia in children evidence update (2014–15), outside of the submitted work. All other authors declare no competing interests. Funding Information: We would like to thank all participants who agreed to take part in the trial. We are grateful to the Psychosis Research Unit Service User Reference Group for their consultation regarding the design of the study and contribution to the development of study materials. We are also grateful to our independent trial steering committee (Graham Murray, Carl Bateson, Susanna Dodd, Rebecca Walwyn, and Alison Brabban) and independent data monitoring committee (Emmanuelle Peters, Thomas R E Barnes, Zak Howarth, and Rod Taylor) for providing oversight of the trial. We also wish to thank the many researchers, network staff, and trial therapists who supported the study (Felicity Waite, Jessica Bird, Sarah Reeve, Peter Cairns, Roger Collin, Leanne Groves, Jon Wilson, Sarah Maxwell, Xavier Coll, Samantha Hartley, Laura Hancox, Robyn Queenan, and Samantha Fraser). This project was funded by the NIHR under its HTA Programme (project number 15/31/04) and will be published in full in the NIHR library HTA journal. Max Birchwood of the MAPS group is funded by the NIHR Applied Research Collaboration West Midlands. The views expressed are those of the author(s) and not necessarily those of the NIHR or the UK Government Department of Health and Social Care. Publisher Copyright: © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Copyright: Copyright 2020 Elsevier B.V., All rights reserved.en
dc.format.extent13
dc.language.isoeng
dc.relation.ispartofThe lancet. Psychiatryen
dc.rightsCopyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectNEGATIVE SYNDROME SCALEen
dc.subjectPANSSen
dc.subjectPREVALENCEen
dc.subjectCHILDRENen
dc.subjectONSETen
dc.subjectR Medicineen
dc.subjectPsychiatry and Mental healthen
dc.subjectBiological Psychiatryen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleAntipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS) : a multicentre, three-arm, randomised controlled pilot and feasibility studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Health Services Research Uniten
dc.contributor.institutionUniversity of Aberdeen.The Centre for Healthcare Randomised Trials (CHaRT)en
dc.contributor.institutionUniversity of Aberdeen.Public Health, Health Services and Primary Careen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S2215-0366(20)30248-0
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85088381551&partnerID=8YFLogxKen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record